Trials / Completed
CompletedNCT00295347
Mineralocorticoid Receptor in the Treatment of Severe Depression
Mineralocorticoid Receptor in the Treatment of Severe Depression: A Randomized, Double Blind, and Placebo Controlled Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 65 (estimated)
- Sponsor
- Universitätsklinikum Hamburg-Eppendorf · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The proposed research aims to compare the onset of action and the efficacy of fludrocortisone, a mineralocorticoid receptor agonist vs. spironolactone, a mineralocorticoid antagonist, vs. placebo as augmentation to a selective serotonin reuptake inhibitor (SSRI) in 65 inpatients with severe depression. The study will also explore the utility of the hypothalamic-pituitary-adrenal (HPA) axis in predicting treatment response. The study will be a 5-week randomized and double-blind trial of fludrocortisone vs. spironolactone vs. placebo during three years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Spironolactone | |
| DRUG | fludrocortisone | |
| DRUG | escitalopram |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2006-02-23
- Last updated
- 2017-05-30
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00295347. Inclusion in this directory is not an endorsement.